Asked by: Baroness Finlay of Llandaff (Crossbench - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what consideration they have given to introducing time-limited interim access pathways for rare cancer treatments where published clinical evidence and specialist expertise already exist but routine commissioning routes are not yet in place.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government supports Scott Arthur’s Private Members Bill on rare cancers which will make it easier for clinical trials into rare cancers, including metastatic ocular melanoma patients, to take place in England by ensuring the patient population can be easily contacted by researchers. This will ensure that the National Health Service will remain at the forefront of medical innovation and is able to provide patients with the newest, most effective treatment options, and ultimately boost survival rates.
The Department remains committed to ensuring that rare cancer patients, including those with metastatic ocular melanoma, have timely access to treatment and tailored medical support.
Tebentafusp is a licensed treatment for uveal melanoma and has been recommended by the National Institute for Health and Care Excellence (NICE) and funded by NHS England since December 2024. Since funding commenced, over 100 patients have been registered to start treatment. At present, NHS England is not aware of any delays in access to Tebentafusp for eligible patients.
Alongside Tebentafusp, a policy proposition for melphalan chemosaturation was accepted onto the NHS England policy development work programme in March 2025, in line with the Methods for National Clinical Policies. Development of this policy is ongoing following receipt of the external evidence review. Progress updates are published through the NHS England Clinical Commissioning Work Programme, and NICE is concurrently updating its guidance. Until revised guidance is issued, the NHS continues to follow the recommendations in the current version.
The development of a Clinical Commissioning policy will determine both if the evidence is now sufficient to enable making the treatment routinely available and, if it is, whether to allocate service development funding to implement it across the NHS in England.
NHS England’s Individual Funding Request (IFR) Policy provides the framework through which requests outside routinely commissioned arrangements are considered. The IFR framework was last reviewed in 2022 and ensures fairness, consistency, and transparency in decision‑making across all applications relating to medicines, devices, or surgical interventions that fall within NHS England’s commissioning responsibilities.
Asked by: Baroness Finlay of Llandaff (Crossbench - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government whether they have considered changes to the use of individual funding requests for rare cancer treatments, particularly the requirement for exceptionality, for patients who have no alternative clinically appropriate treatment options.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government supports Scott Arthur’s Private Members Bill on rare cancers which will make it easier for clinical trials into rare cancers, including metastatic ocular melanoma patients, to take place in England by ensuring the patient population can be easily contacted by researchers. This will ensure that the National Health Service will remain at the forefront of medical innovation and is able to provide patients with the newest, most effective treatment options, and ultimately boost survival rates.
The Department remains committed to ensuring that rare cancer patients, including those with metastatic ocular melanoma, have timely access to treatment and tailored medical support.
Tebentafusp is a licensed treatment for uveal melanoma and has been recommended by the National Institute for Health and Care Excellence (NICE) and funded by NHS England since December 2024. Since funding commenced, over 100 patients have been registered to start treatment. At present, NHS England is not aware of any delays in access to Tebentafusp for eligible patients.
Alongside Tebentafusp, a policy proposition for melphalan chemosaturation was accepted onto the NHS England policy development work programme in March 2025, in line with the Methods for National Clinical Policies. Development of this policy is ongoing following receipt of the external evidence review. Progress updates are published through the NHS England Clinical Commissioning Work Programme, and NICE is concurrently updating its guidance. Until revised guidance is issued, the NHS continues to follow the recommendations in the current version.
The development of a Clinical Commissioning policy will determine both if the evidence is now sufficient to enable making the treatment routinely available and, if it is, whether to allocate service development funding to implement it across the NHS in England.
NHS England’s Individual Funding Request (IFR) Policy provides the framework through which requests outside routinely commissioned arrangements are considered. The IFR framework was last reviewed in 2022 and ensures fairness, consistency, and transparency in decision‑making across all applications relating to medicines, devices, or surgical interventions that fall within NHS England’s commissioning responsibilities.
Asked by: Baroness Finlay of Llandaff (Crossbench - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of the impact of delays in commissioning decisions on (1) outcomes, and (2) quality of life, for patients with rare cancers.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government supports Scott Arthur’s Private Members Bill on rare cancers which will make it easier for clinical trials into rare cancers, including metastatic ocular melanoma patients, to take place in England by ensuring the patient population can be easily contacted by researchers. This will ensure that the National Health Service will remain at the forefront of medical innovation and is able to provide patients with the newest, most effective treatment options, and ultimately boost survival rates.
The Department remains committed to ensuring that rare cancer patients, including those with metastatic ocular melanoma, have timely access to treatment and tailored medical support.
Tebentafusp is a licensed treatment for uveal melanoma and has been recommended by the National Institute for Health and Care Excellence (NICE) and funded by NHS England since December 2024. Since funding commenced, over 100 patients have been registered to start treatment. At present, NHS England is not aware of any delays in access to Tebentafusp for eligible patients.
Alongside Tebentafusp, a policy proposition for melphalan chemosaturation was accepted onto the NHS England policy development work programme in March 2025, in line with the Methods for National Clinical Policies. Development of this policy is ongoing following receipt of the external evidence review. Progress updates are published through the NHS England Clinical Commissioning Work Programme, and NICE is concurrently updating its guidance. Until revised guidance is issued, the NHS continues to follow the recommendations in the current version.
The development of a Clinical Commissioning policy will determine both if the evidence is now sufficient to enable making the treatment routinely available and, if it is, whether to allocate service development funding to implement it across the NHS in England.
NHS England’s Individual Funding Request (IFR) Policy provides the framework through which requests outside routinely commissioned arrangements are considered. The IFR framework was last reviewed in 2022 and ensures fairness, consistency, and transparency in decision‑making across all applications relating to medicines, devices, or surgical interventions that fall within NHS England’s commissioning responsibilities.
Asked by: Baroness Maclean of Redditch (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of the influence of (1) social media, and (2) greater public awareness, on self-diagnosis and subsequent formal diagnosis of mental health conditions; and what guidance they have provided to clinicians about those influences.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
In 2019, the UK Chief Medical Officers published a commentary on the findings of a systematic review on screen-based activities and children’s mental health. They found an association between screen-based activities and mental health but could not establish causality. The commentary is avaiable in the document attached.
On 20 January 2026, the Government announced a forthcoming consultation on how to ensure children have a healthy relationship with devices, introduce rapid trials on measures to reduce screentime and limit access at night, and produce evidence-informed screentime guidance for parents of children aged five to 16 years old. This three-month consultation will be evidence-led, with input from independent experts, and will include determining the right minimum age for children to access social media. It will report in the summer.
Over the past decade, greater public awareness and reduced stigma around mental health have coincided with a rise in common mental health conditions and increased demand for National Health Service support, highlighting the need to better understand and address people’s needs.
The independent review into the prevalence and support for mental health conditions, attention deficit hyperactivity disorder, and autism will therefore examine a range of potential drivers of mental health conditions, the impact of clinical practice, including the role of diagnosis, opportunities for prevention and early intervention, and models of support within and beyond the NHS.
The review’s Terms of Reference are published on the GOV.UK website, in an online only format.
Asked by: Martin Wrigley (Liberal Democrat - Newton Abbot)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what support is being provided to (a) Torbay and (b) Exeter NHS Trusts to recruit and retain specialist cancer nurses and the cancer workforce.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
NHS England has made good progress in growing and developing the cancer and diagnostics workforce.
In 2024/25, approximately 8,000 people received training to either enter the cancer and diagnostics workforce or develop in their roles. As part of this, over 1,600 people were on apprenticeship courses, with over 270 additional medical specialty training places funded. Over 1,000 clinical nurse specialist (CNS) grants were made available to new and aspiring CNSs across England, including Devon.
We are working to end the postcode lottery for cancer services. NHS England is working with NHS regions and the royal colleges to increase the number of clinical and medical oncology staff overall. In addition, we aim to fill vacancies and expand workforces in trusts that most need more staff, including in rural and coastal areas, to help boost performance.
Asked by: Helen Maguire (Liberal Democrat - Epsom and Ewell)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions he has had with NHS England on the publication date for the draft commissioning policy for Chemosaturation therapy.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department and the National Health Service in England are committed to ensuring that cancer patients have timely access to treatment and tailored medical support. In 2016, NHS England concluded that there was insufficient evidence to make chemosaturation treatment available to patients on the NHS. NHS England is currently in the early stages of policy development for chemosaturation to treat metastatic uveal melanoma where surgery to remove or destroy affected cells and tissue in the liver is not feasible.
National Institute for Health and Care Excellence (NICE) guidance recommends that chemosaturation can be used for patients with secondary liver metastases resulting from a primary ocular melanoma, provided special arrangements are in place. A special arrangements recommendation states that clinicians using the procedure should inform the clinical governance lead in their trust, tell the patient about the uncertainties regarding the safety and efficacy of the procedure, and collect further data by means of audit or research. NICE is in the process of updating its guidance, with final guidance expected on 15 October 2026. The first committee meeting, to discuss the evidence, is expected to take place on 16 April 2026. Further information is available at the following link:
https://www.nice.org.uk/guidance/indevelopment/gid-ipg10448
Asked by: Callum Anderson (Labour - Buckingham and Bletchley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what funding has been allocated to cancer care infrastructure in Buckingham and Bletchley constituency in the next three financial years.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Improving cancer services, including diagnostic capacity and treatment infrastructure, is a priority for the Government.
The Government is committed to meeting all three National Health Service cancer waiting time standards across England. We are committed to transforming diagnostic services and will support the NHS to meet demand through investment in new capacity, including magnetic resonance imaging and computed tomography scanners. As of December 2025, community diagnostic centres are now delivering additional tests and checks on 170 sites across the country.
The forthcoming National Cancer Plan will set out further details as to how patients across England, including in Buckingham and Bletchley, will benefit from improved diagnostic services and cancer care infrastructure.
Funding for cancer pathways is multi-layered. The integrated care board uses the core Government allocation to commission services from providers, including cancer-related activity. Specialised commissioning directs funding towards specialist areas of healthcare, such as paediatric oncology and chemotherapy.
The East of England Cancer Alliance has been allocated approximately £16 million of revenue funds for 2026/27 which will support targeted programmes of work. The process to allocate these funds is currently live. System priorities have been identified and funding requests have been submitted for consideration.
Asked by: Callum Anderson (Labour - Buckingham and Bletchley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve diagnostic services for cancer in Buckingham and Bletchley constituency.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Improving cancer services, including diagnostic capacity and treatment infrastructure, is a priority for the Government.
The Government is committed to meeting all three National Health Service cancer waiting time standards across England. We are committed to transforming diagnostic services and will support the NHS to meet demand through investment in new capacity, including magnetic resonance imaging and computed tomography scanners. As of December 2025, community diagnostic centres are now delivering additional tests and checks on 170 sites across the country.
The forthcoming National Cancer Plan will set out further details as to how patients across England, including in Buckingham and Bletchley, will benefit from improved diagnostic services and cancer care infrastructure.
Funding for cancer pathways is multi-layered. The integrated care board uses the core Government allocation to commission services from providers, including cancer-related activity. Specialised commissioning directs funding towards specialist areas of healthcare, such as paediatric oncology and chemotherapy.
The East of England Cancer Alliance has been allocated approximately £16 million of revenue funds for 2026/27 which will support targeted programmes of work. The process to allocate these funds is currently live. System priorities have been identified and funding requests have been submitted for consideration.
Asked by: Baroness Maclean of Redditch (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government by how much demand for mental health, ADHD and autism services is increasing or decreasing in each of the past five years for people aged (1) under 16, (2) 16-24, (3) 25-34, (4) 35-49, (5) 50-64, and (6) over 65.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The following table shows the number of people in contact with National Health Service funded secondary mental health, learning disabilities and autism services, in each financial year between 2020/21 and 2024/25:
Age group | 2020/21 | 2021/22 | 2022/23 | 2023/24 | 2024/25 |
Under 16 years old | 593,297 | 776,750 | 869,206 | 915,617 | 986,814 |
16-24 years old | 499,690 | 595,233 | 642,990 | 640,187 | 678,667 |
25-34 years old | 385,511 | 438,756 | 500,668 | 542,170 | 606,461 |
35-49 years old | 424,031 | 466,396 | 525,588 | 581,642 | 661,362 |
50-64 years old | 331,311 | 357,524 | 388,097 | 418,523 | 449,505 |
65 years old and over | 563,811 | 609,373 | 647,310 | 675,575 | 685,797 |
UNKNOWN | 5,593 | 12,663 | 9,005 | 17,112 | 60,684 |
Source: Mental Health Services Data Set (MHSDS)
Notes:
The following table shows the number of people known to be in contact with NHS Talking Therapies in each financial year between 2020/21 and 2024/25:
Age group | 2020/21 | 2021/22 | 2022/23 | 2023/24 | 2024/25 |
|
Under 16 years old | 1,222 | 1,189 | 925 | 886 | 749 |
|
16-24 years old | 360,673 | 424,826 | 398,859 | 370,377 | 350,213 |
|
25-34 years old | 487,273 | 571,094 | 563,973 | 555,142 | 543,044 |
|
35-49 years old | 437,838 | 514,275 | 537,364 | 564,755 | 583,614 |
|
50-64 years old | 265,491 | 311,633 | 332,821 | 358,120 | 366,773 |
|
65 years old and over | 89,446 | 108,885 | 123,740 | 136,297 | 140,262 |
|
Source: Improving Accessing to Psychological Therapies dataset Notes:
| ||||||
Asked by: Anneliese Dodds (Labour (Co-op) - Oxford East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, in regard to the upcoming closure of the the UK Rare Diseases Framework, what alternative evaluation methods will be used to assess and ensure the continued improvement of access to specialist care, treatment and drugs for patients with rare diseases.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The UK Rare Diseases Framework was published following the National Conversation on Rare Diseases, which received nearly 6,300 responses. This helped identify the four priorities of the framework in tackling rare diseases: helping patients get a final diagnosis faster; increasing awareness of rare diseases among healthcare professionals; better coordination of care; and improving access to specialist care, treatment, and drugs.
The Government remains committed to improving the lives of those living with rare conditions, and will be publishing the next England Rare Diseases Action Plan to update on these priorities as in previous years. The evaluation of England’s action plans is expected to complete in May 2026. We recognise that despite the progress that has been made there remains considerable unmet need for people living with rare conditions. Ministers from all four nations have agreed to extend the UK Rare Diseases Framework by one year to January 2027, recognising the continued relevance of its four priorities, including improving access to specialist care, treatment, and drugs. We will engage with the rare diseases community to help shape the next steps.